DMRA
Damora TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
The bull case is that Damora now has a well-funded post-merger platform, stated cash of $257.6 million at December 31, 2025, runway said to extend into Phase 3 development of DMR-001, and a clear mid-2026 IND/CTA target for the lead mutCALR program, leaving room for a sharp rerating if execution stays on schedule [#10-K-2026-03-19].
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +7.9.
What can break
Cash runway could shorten if development pace or operating spend rises faster than planned
Momentum
94
Value
41
Sentiment
24
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $24.00 · Bull $38.00 · Bear $14.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $43.38
Why
Momentum94 · Δ7d +7.9
Value41 · Δ7d -0.1
Sentiment24 · Δ7d -10.2
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
94
26% active weight
Current posture
7d trendImproving
Δ7d
+7.9
Δ21d
+72.4
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
24
34% active weight
Current posture
7d trendSoftening
Δ7d
-10.2
Δ21d
-19.5
Why this grade
Composite grade C. Momentum 94.1 / Value 41.1 / Sentiment 24.3
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$1.94B
Beta
1.43
Shares Out
61.57M
P/E (TTM) · Derived
-0.2
P/S (TTM)
-
P/FCF (TTM) · Derived
-8.03
Rev YoY
-
EPS YoY
-57.8%
Gross Margin
-
Op Margin
-
Net Debt
-$256.21M
Current Ratio
22.48
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology